CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)

Lignende værker

• Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
  af: Tsuboi, Kazuya, et al.
  Udgivet: (2012)
• Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta (Fabrazyme(®)) to Agalsidase Alfa (Replagal(®))
  af: Tsuboi, Kazuya, et al.
  Udgivet: (2014)
• Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
  af: Pastores, Gregory M
  Udgivet: (2007)
• Effects of Switching from Agalsidase Beta to Agalsidase Alfa in 10 Patients with Anderson-Fabry Disease
  af: Pisani, A., et al.
  Udgivet: (2012)
• Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta
  af: Limgala, Renuka P, et al.
  Udgivet: (2019)